Raspberry ketone protects rats fed high-fat diets against nonalcoholic steatohepatitis

Journal of Medicinal Food

Volumn 15, Issue 5, 2012, Pages 495-503

  Wang, Lili ^a,b   Meng, Xianjun ^a   Zhang, Fengqing ^b  

^a SHENYANG AGRICULTURAL UNIVERSITY   (China)

^b Shenyang Product Quality Supervision and Inspection Institute   (China)

Author keywords

nonalcoholic steatohepatitis; raspberry ketone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMATOXYLIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; KETONE DERIVATIVE; LEPTIN; LIPID; LIVER PROTECTIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RASPBERRY KETONE; SUPEROXIDE DISMUTASE; TAUROCHOLIC ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL DEGENERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; DYSLIPIDEMIA; ELECTRON MICROSCOPY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID DIET; LIVER CELL; LIVER FUNCTION; LIVER HOMOGENATE; LIVER PROTECTION; LOW DRUG DOSE; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RASPBERRY; RAT; SPRAGUE DAWLEY RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BUTANONES; C-REACTIVE PROTEIN; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; FRUIT; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; ROSACEAE; TRANSAMINASES; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS; RUBUS GLAUCUS;

EID: 84860557857     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2011.1717     Document Type: Article

References (38)

1. Lu LT: A study on the genus Rubus of China. J System Evol 1983;21:13-25.
2. Gu Y, Li WL, Wang CY, Yu H, Shi ZM, Peng LJ: Investigation on wild Rubus resources in Yunnan province. Plant Sci J 2000;18:49-55.
3. Gallois A: Quantitative evaluation of raspberry ketone using thin-layer chromatography. Sci Aliments 1982;2:99-106.
4. Guichard E: Identification of the flavoured volatile components of the raspberry cultivar Lloyd George. Sci Aliments 1982;2:173-185.
5. Sporstol S, Scheline RR: The metabolism of 4-(4-hydroxyphenyl) butan-2-one (raspberry ketone) in rats, guinea-pigs and rabbits. Xenobiotica 1982;12:249-257.
6. Beekwilder J, van der Meer IM, Sibbesen O, Broekgaarden M, Qvist I, Mikkelsen JD, Hall RD: Microbial production of natural raspberry ketone. Biotechnol J 2007;10:1270-1279.
7. Morimoto C, Satoh Y, Hara M Inoue S, Tsujita T, Okuda H: Anti-obese action of raspberry ketone. Life Sci 2005;77:194-204.
8. Meng XJ, Zhou Y, Liu X, Zheng F: Experimental study on the anti-obesity action of simple obesity in rats by raspberry ketone. Food Industry 2008;1:1-3.
9. Zhou Y, Meng XJ, Liu X, Li B: Experimental study on the intervention of nonalcoholic steatohepatitis in rats by raspberry ketone. Food Industry 2008;2:6-9.
10. Nonalcoholic steatohepatitis clinical research network. Hepatology 2003;37:224.
11. Sanyal AJ: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725.
12. Pulzi FBU, Cisternas R, Melo MR, Ribeiro CMF, Malheiros CA, Salles JE: New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetol Metab Syndr 2011;3:3.
13. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-145.
14. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
15. Younossi ZM, Diehl AM, Ong JP: Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35: 746-752.
16. Hojo M, Watanabe S: Pharmacological therapy of nonalcoholic steatohepatitis. Hepatol Res 2011;41:209-216.
17. Fan JG, Ding XD, Zeng Y: Nonalcoholic steatohepatitis: Society of American symposium on liver disease [in Chinese]. Liver 2003;8:59-61.
18. Ni YJ, Liu HY, Zhang SC, et al.: Hepatic lipase and lipoprotein lipase in the pathogenesis of fatty liver [in Chinese]. Chin J Digest 1999;19:324-327.
19. Rouach H, Fataccioli V, Gentil M, French SW, Morimoto M, Nordmann R: Effect of chronic ethanol feeding on lipid peroxidation and protein oxidation in relation to liver pathology. Hepatology 1997;25:351-355.
20. Pérez-Aguilar FF: Etiopathogenesis of non-alcoholic steatohepatitis [in Spanish]. Gastroenterol Hepatol 2005;28:396-406.
21. Marchesini G, Marzocchi R, Agostini F, Bugianesi E: Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-427.
22. Ni YJ, Liu HY: Pathogenesis of fatty liver and the diagnosis and treatment [in Chinese]. Int J Dig Dis 1997;17:158-161.
23. Li YM: Lipid-lowering drugs used in the treatment of fatty liver in the conflict [in Chinese]. Modern Med Health 2003;19:127-128.
24. Yan M, Lu R, Jia X, Meng F, Zhao X: Different serum lipid adjustment drugs for the treatment of hyperlipidemic fatty liver [in Chinese]. Chin J Hepatol 2001;9:355-357.
25. Zhao XW: Diagnosis and treatment of fatty liver in progress [in Chinese]. J Trad Chin Med 2002;43:943-945.
26. Yang HY, Tzeng YH, Chai CY, Hsieh AT, Chen JR, Chang LS, Yang SS: Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. Nutrition 2011;2:16.
27. Day CP, James OF: Steatohepatitis: a tale of two ''hits''? Gastroenterology 1998;114:842-845.
28. Park KS: Raspberry ketone increases both lipolysis and fatty acid oxidation in 3T3-L1 adipocytes. Planta Med 2010;76: 1654-1658.
29. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ: PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 2011;141:603-610.
30. Fukumitsu S, Aida K, Shimizu H, Toyoda K: Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice. Br J Nutr 2008;100:669-676.
31. Sturzeneker MC, Ioshii SO, Villela Baroncini LA, Précoma DB: Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis 2011;2:19.
32. Xu C, Wang G, Hao Y, Zhi J, Zhang L, Chang C: Correlation analysis between gene expression profile of rat liver tissues and high-fat emulsion-induced nonalcoholic fatty liver. Dig Dis Sci 2011;56:2299-2308.
33. Ji G, Yang Q, Hao J, Guo L, Xhen X, Hu J, Leng L, Jiang Z: Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol 2011;11:762-768.
34. Adams LA, Angulo P, Lindor KD: Nonalcoholic fatty liver disease. Can Med Assoc J 2005;173:734-745.
35. Siebler J, Galle PR: Treatment of nonalcoholic fatty liver disease. World Gastroenterol 2006;12:2161-2167.
36. Adams LA, Angulo P: Treatment of non-alcoholic fatty liver disease. J Postgrad Med 2006;82:315-322.
37. Zhang YX, Li ZK: The recent study on fatty liver [in Chinese]. Inner Mongolia Med J 2006;38:459-461.
38. Liu HC, Yan JR, Xu N: Comparative study of effects and safety of atorvastatin and fluvastatin on aged patients with hyperlipidemia [in Chinese]. Chin J Modern Med 2006;14:133-l37